Acorda Therapeutics to Showcase Online Multiple Sclerosis Resources at 2014 CMSC/ACTRIMS Meeting

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR), a biotechnology company based in New York, will provide demonstrations of its award-winning digital tools for multiple sclerosis (MS) disease management at the 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), being held May 2831 in Dallas, Texas. Demonstrations of MoveOverMS.org and the MS self multiple sclerosis app will be held in the MoveOverMS.org booth (#406) in the meeting exhibit hall.

MoverOverMS.org offers a multitude of tools to help those living with MS, including videos, articles and downloadable information. The MS self mobile app features informative fact cards, achievement badges, and an interactive journal that allows users to log moods, thoughts and activities. The app has recently been updated on the iTunes app store with new features and is free to download.

We developed MoveOverMS.org and MS self to help people proactively manage the challenges they face living with MS. We are excited to share these digital tools with the healthcare professionals attending the CMSC/ACTRIMS meeting, providing them with additional resources for their patients, said Adrian Rabinowicz, Acordas Senior Vice President, Clinical Development and Medical Affairs. Our companys mission is to improve the lives of people with neurological disorders. Research and development of novel medicines is a core component of our mission, as is providing support to people with MS, their care partners and healthcare team.

About CMSC

The Consortium of Multiple Sclerosis Centers (CMSC) is the leading educational, training, and networking organization for MS healthcare professionals and researchers. The CMSCs mission is to promote quality multiple sclerosis care through educational programming and accreditation, including live and online events, research grants, technical journals and papers, and targeted advocacy efforts. The CMSC member network includes more than 7,000 international healthcare clinicians and scientists committed to multiple sclerosis care as well as more than 60 Veterans Administration MS Programs and 225 MS Centers in the U.S., Canada, and Europe.

About ACTRIMS

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) provides leadership in the field of multiple sclerosis and other demyelinating diseases. MS clinicians and researchers founded ACTRIMS to serve as the U.S. and Canadian counterpart to ECTRIMS, the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS). The annual ACTRIMS meeting provides a forum to exchange information, debate current issues, and discuss advances related to basic and clinical issues in MS research.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies including: AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA (capsaicin) 8% Patch for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

Excerpt from:
Acorda Therapeutics to Showcase Online Multiple Sclerosis Resources at 2014 CMSC/ACTRIMS Meeting